Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") today announced that it will present a poster on Phase 2 results for AEZS-108 in advanced endometrial cancer at the 22^nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held at the Berlin Estrel Hotel and Convention Centre in Berlin, Germany November 16 through 19, 2010.

AEZS-108, a novel hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, is in a Phase 2 trial in advanced endometrial. For more information on the trial, go to http://www.clinicaltrials.gov/ct2/results?term=AEZS-108. AEZS-108 is the first intravenous drug in a clinical study that directs the chemotherapy agent specifically to luteinizing hormone-releasing hormone (LHRH)-receptor expressing tumors, resulting in more targeted treatment with less damage to healthy tissue. AEZS-108, also in a Phase 2 trial in advanced ovarian cancer, has been granted orphan-drug designation by the U.S. Food and Drug Administration and orphan medicinal product designation from the European Medicines Agency for this indication. Aeterna Zentaris owns the worldwide rights to AEZS-108.

In addition to the poster on AEZS-108, the Company will also present posters on preclinical results for three of its other novel anticancer compounds: